Trending Now
Latest News
AbbVie CFO Chase spearheaded its Abbott spinoff and Imbruvica buy—and now...
AbbVie has been on quite the ride since its spinoff from Abbott, largely thanks to booming growth for its megablockbuster Humira. Now, the company’s chief...
PhaseBio goes public in downsized offering of $46 million
A biotechnology company developing therapies for pulmonary arterial hypertension and for bleeding in patients taking antiplatelet therapy has made its initial public offering, albeit...
More
AbbVie CFO Chase spearheaded its Abbott spinoff and Imbruvica buy—and now he’s retiring
AbbVie has been on quite the ride since its spinoff from Abbott, largely thanks to booming growth for its megablockbuster Humira. Now, the company’s chief...
PhaseBio goes public in downsized offering of $46 million
A biotechnology company developing therapies for pulmonary arterial hypertension and for bleeding in patients taking antiplatelet therapy has made its initial public offering, albeit...
Viseon gets FDA nod for Voyant system for minimally invasive spine surgery
Viseon has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Voyant system for minimally invasive spine surgery.
...
Major research study aims to develop new electrical type 2 diabetes treatments
A $2.9m research project aiming to find ways to prevent and treat type 2 diabetes using electronic devices is underway.Global giant General...
